Lupartumab amadotin - Bayer HealthCare

Drug Profile

Lupartumab amadotin - Bayer HealthCare

Alternative Names: Anti-C4.4a antibody-drug conjugates - Bayer; Anti-LY6-PLAUR domain containing 3 antibody-drug conjugates - Bayer; Anti-LYPD3 antibody-drug conjugates - Bayer; BAY 1129980; LYPD3 protein-directed antibody-drug conjugates - Bayer

Latest Information Update: 28 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer HealthCare
  • Class Antineoplastics; Auristatins; Immunoconjugates
  • Mechanism of Action LYPD3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in USA (IV)
  • 01 Apr 2017 Pharmacodynamics data from a preclinical study in Solid tumours presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 21 Oct 2015 Phase-I development for Solid tumours (Late-stage disease) is ongoing in USA (NCT02134197)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top